Skip to main content
. 2021 Oct 18;12:754436. doi: 10.3389/fimmu.2021.754436

Table 1.

Current checkpoint inhibitors with regulatory approval.

Target Checkpoint Inhibitor Year of first FDA approval
PD-1 Pembrolizumab 2014
Nivolumab 2014
Cemiplimab 2018
Dostarlimab 2021
PD-L1 Atezolizumab 2016
Durvalumab 2017
Avelumab 2017
CTLA-4 Ipilimumab 2011